HLA-B27: a registry of constitutive peptide ligands.

The very strong association of human leukocyte antigen (HLA)-B27 with spondyloarthritis might be related to its peptide-presenting properties. The natural polymorphism of this molecule influences both peptide specificity and disease susceptibility. In this study, we present a comprehensive compilation of known natural ligands of HLA-B27 arising from endogenous proteins of human cells, together with a statistical assessment of residue usage among constitutive peptide repertoires of multiple HLA-B27 subtypes. This analysis provides evidence that every peptide position, including "non-anchor" ones, may be subjected to selection on the basis of its contribution to HLA-B27 binding and also allows a quantization of residue preferences at known anchor positions. The present registry is intended as a basis on which to build up reliable criteria to assess the effect of HLA-B27 polymorphism on peptide presentation, for T-cell epitope predictions, and for molecular mimicry studies.

[1]  V. Gnau,et al.  Dominant aromatic/aliphatic C-terminal anchor in HLA-B*2702 and B*2705 peptide motifs , 2004, Immunogenetics.

[2]  J. Albar,et al.  Modulation of peptide binding by HLA‐B27 polymorphism in pockets A and B, and peptide specificity of B*2703 , 1995, European journal of immunology.

[3]  J. Hansen,et al.  Structural analysis of an HLA-B27 functional variant, B27d, detected in American blacks. , 1987, Journal of immunology.

[4]  William S. Lane,et al.  Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle , 1992, Nature.

[5]  M. Ramos,et al.  HLA-B27 and the pathogenesis of spondyloarthritis. , 2002, Tissue antigens.

[6]  S. Rowland-Jones,et al.  Differences in peptide presentation between B27 subtypes: the importance of the P1 side chain in maintaining high affinity peptide binding to B*2703. , 1994, Immunity.

[7]  D. Rognan,et al.  An HLA-B27 polymorphism (B*2710) that is critical for T-cell recognition has limited effects on peptide specificity. , 1998, Tissue antigens.

[8]  Paul Wordsworth,et al.  The nucleotide sequence of HLA-B*2704 reveals a new amino acid substitution in exon 4 which is also present in HLA-B*2706 , 2004, Immunogenetics.

[9]  Forest M. White,et al.  Phosphorylated Peptides Are Naturally Processed and Presented by Major Histocompatibility Complex Class I Molecules in Vivo , 2000, The Journal of experimental medicine.

[10]  M. Ramos,et al.  Limited Diversity of Peptides Related to an Alloreactive T Cell Epitope in the HLA-B27-Bound Peptide Repertoire Results from Restrictions at Multiple Steps Along the Processing-Loading Pathway1 , 2000, The Journal of Immunology.

[11]  V. Montserrat,et al.  Large sharing of T-cell epitopes and natural ligands between HLA-B27 subtypes (B*2702 and B*2705) associated with spondyloarthritis. , 2001, Tissue antigens.

[12]  M. Marcilla,et al.  Species-specific Differences in Proteasomal Processing and Tapasin-mediated Loading Influence Peptide Presentation by HLA-B27 in Murine Cells* , 2003, Journal of Biological Chemistry.

[13]  D. R. Madden,et al.  Identification of self peptides bound to purified HLA-B27 , 1991, Nature.

[14]  A. Goldberg,et al.  Degradation of cell proteins and the generation of MHC class I-presented peptides. , 1999, Annual review of immunology.

[15]  A. Toubert,et al.  Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic variants. Implications for susceptibility to spondylarthropathies. , 1996, The Journal of clinical investigation.

[16]  Forest M. White,et al.  Immunodominance Among EBV-Derived Epitopes Restricted by HLA-B27 Does Not Correlate with Epitope Abundance in EBV-Transformed B-Lymphoblastoid Cell Lines1 , 2000, The Journal of Immunology.

[17]  J. Albar,et al.  HLA-B27 presents a peptide from a polymorphic region of its own molecule with homology to proteins from arthritogenic bacteria. , 1997, Tissue antigens.

[18]  James McCluskey,et al.  Optimization of the MHC class I peptide cargo is dependent on tapasin. , 2002, Immunity.

[19]  J. Shabanowitz,et al.  Differences in the Expression of Human Class I MHC Alleles and Their Associated Peptides in the Presence of Proteasome Inhibitors1 , 2001, The Journal of Immunology.

[20]  R. Bragado,et al.  Molecular analysis of a functional subtype of HLA-B27. A possible evolutionary pathway for HLA-B27 polymorphism. , 1986, Journal of immunology.

[21]  R. Tampé,et al.  Affinity, Specificity, Diversity: A Challenge for the ABC Transporter TAP in Cellular Immunity , 2000, Chembiochem : a European journal of chemical biology.

[22]  Euijae Kim,et al.  A Single Polymorphic Residue Within the Peptide-Binding Cleft of MHC Class I Molecules Determines Spectrum of Tapasin Dependence1 , 2003, The Journal of Immunology.

[23]  F. Roncal,et al.  Modulation at multiple anchor positions of the peptide specificity of HLA-B27 subtypes differentially associated with ankylosing spondylitis. , 1999, Arthritis and rheumatism.

[24]  P. Parham,et al.  Guilt by association: HLA-B27 and ankylosing spondylitis. , 1990, Immunology today.

[25]  Dean R. Madden,et al.  The three-dimensional structure of HLA-B27 at 2.1 Å resolution suggests a general mechanism for tight peptide binding to MHC , 1992, Cell.

[26]  W. Saenger,et al.  Thermodynamic and Structural Analysis of Peptide- and Allele-dependent Properties of Two HLA-B27 Subtypes Exhibiting Differential Disease Association* , 2004, Journal of Biological Chemistry.

[27]  C. Vilches,et al.  Nucleotide sequence of HLA-B*2706 , 2004, Immunogenetics.

[28]  J. Sidney,et al.  Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.

[29]  Erin L. Schenk,et al.  HLA class I polymorphism has a dual impact on ligand binding and chaperone interaction. , 2002, Human immunology.

[30]  E. Camafeita,et al.  Identification of Novel HLA-B27 Ligands Derived from Polymorphic Regions of Its Own or Other Class I Molecules Based on Direct Generation by 20 S Proteasome* , 2001, The Journal of Biological Chemistry.

[31]  J. Albar,et al.  HLA-B27 (B*2701) specificity for peptides lacking Arg2 is determined by polymorphism outside the B pocket. , 1997, Tissue antigens.

[32]  M. Garcia-Peydró,et al.  Quantitative and Qualitative Influences of Tapasin on the Class I Peptide Repertoire1 , 2001, The Journal of Immunology.

[33]  W. Klitz,et al.  HLA-DR and -DQ polymorphism in Cameroon. , 2001, Tissue antigens.

[34]  E. Camafeita,et al.  The Cys-67 Residue of HLA-B27 Influences Cell Surface Stability, Peptide Specificity, and T-cell Antigen Presentation* , 2001, The Journal of Biological Chemistry.

[35]  A. Marina,et al.  Differential Association of HLA-B*2705 and B*2709 to Ankylosing Spondylitis Correlates with Limited Peptide Subsets but Not with Altered Cell Surface Stability* , 2002, The Journal of Biological Chemistry.

[36]  A. Marina,et al.  Lack of carboxyl-terminal tyrosine distinguishes the B*2706-bound peptide repertoire from those of B*2704 and other HLA-B27 subtypes associated with ankylosing spondylitis. , 1997, Tissue antigens.

[37]  H. Orr,et al.  Molecular analysis of the variant alloantigen HLA-B27d (HLA-B*2703) identifies a unique single amino acid substitution. , 1988, Human immunology.

[38]  Wolfram Saenger,et al.  HLA-B27 Subtypes Differentially Associated with Disease Exhibit Subtle Structural Alterations* , 2002, The Journal of Biological Chemistry.

[39]  J. Shabanowitz,et al.  Susceptibility to ankylosing spondylitis correlates with the C‐terminal residue of peptides presented by various HLA‐B27 subtypes , 1997, European journal of immunology.

[40]  D. Rognan,et al.  The same natural ligand is involved in allorecognition of multiple HLA-B27 subtypes by a single T cell clone: role of peptide and the MHC molecule in alloreactivity. , 1998, Journal of immunology.

[41]  L. Tuosto,et al.  Identification of a novel HLA-B27 subtype by restriction analysis of a cytotoxic gamma delta T cell clone. , 1994, Journal of immunology.

[42]  R. Bragado,et al.  Delineation of functional sites in HLA-B27 antigens. Molecular analysis of HLA-B27 variant Wewak I defined by cytolytic T lymphocytes. , 1985, Journal of immunology.

[43]  A. Marina,et al.  The Peptide Repertoires of HLA-B27 Subtypes Differentially Associated to Spondyloarthropathy (B*2704 and B*2706) Differ by Specific Changes at Three Anchor Positions* , 2002, The Journal of Biological Chemistry.

[44]  D. R. Madden,et al.  The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation , 1991, Nature.

[45]  J. Penninger,et al.  Chlamydia infections and heart disease linked through antigenic mimicry. , 1999, Science.

[46]  D. Rognan,et al.  Molecular Mimicry of an HLA-B27-derived Ligand of Arthritis-linked Subtypes with Chlamydial Proteins* , 2002, The Journal of Biological Chemistry.

[47]  A. Toubert,et al.  HLA-B*2707 peptide motif: Tyr C-terminal anchor is not shared by all disease-associated subtypes , 1997, Immunogenetics.

[48]  H. Rammensee,et al.  Naturally occurring A pocket polymorphism in HLA-B*2703 increases the dependence on an accessory anchor residue at P1 for optimal binding of nonamer peptides. , 1997, Journal of immunology.

[49]  D. Madden.  The three-dimensional structure of peptide-MHC complexes. , 1995, Annual review of immunology.